# Chronic kidney disease in hypertensive patients: the urgent need for targeted interventions in Arab countries: a systematic review

**Authors:** Fakhria Al Rashdi, Celine Tabche, Zeenah Atwan, Hamed Al-Qanubi, Samiya Al Khaldi, Nasrin Al-Zadjali, Salman Rawaf

PMC · DOI: 10.3389/fneph.2026.1735217 · Frontiers in Nephrology · 2026-02-09

## TL;DR

Chronic kidney disease is a growing health issue in Arab countries, with high rates among people with hypertension, and many cases go undiagnosed.

## Contribution

This systematic review highlights the urgent need for region-specific screening and hypertension control programs in Arab countries to address CKD.

## Key findings

- 38.8% of hypertensive patients had unrecognized CKD, and nearly 39% of 400 participants had undiagnosed stages 3–5 CKD.
- Physicians reported suboptimal screening rates, with 77% relying on estimated glomerular filtration rate as a diagnostic tool.
- Hypertension is a major risk factor for CKD, with 55.8% and 75% of identified CKD patients having HTN in two studies.

## Abstract

Chronic kidney disease (CKD) is expected to be the 5th leading cause of years of life lost by 2040. Recently, it emerged as a significant cause of mortality and morbidity, with a high prevalence in Arab countries.

Assess CKD among hypertensive (HTN) people in Arab Countries through evaluation of the existing literature on CKD prevalence, risk factors, screening programmes and prevention.

A systematic review till April 2024 following PRISMA guidelines. The search strategy was registered in PROSPERO under the identification code CRD42024486068.

Databases searched were Medline, Embase, Scopus, PubMed, Cochrane Library. Screening was done using Covidence by three independent reviewers.

Out of 63 studies screened, 11 were selected for extraction. The prevalence of CKD was higher among elderly, HTN and diabetic patients, with 38.8% having unrecognised CKD. Nearly 39% of the 400 participants in one study had undiagnosed stages 3–5 CKD. Two studies showed that 55.8% and 75% of identified CKD patients had HTN. Physicians reported suboptimal screening rates, with about 77% relying on the estimated glomerular filtration rate as a diagnostic tool. Risk factors for CKD include old age, HTN, dyslipidaemia, family history of CKD, and obesity. Among physicians, 85% recommended a target blood pressure of ≤130/80, 80% advised smoking cessation, 66% prescribed anti-lipids, and 67% recommended weight loss. All studies support the fact that HTN is a risk factor for CKD.

CKD is an escalating problem in Arab countries, with hypertension as a major risk factor. Many patients remain undiagnosed. A region-specific CKD screening and HTN control programme is urgently needed. The findings are essential for policymakers in strengthening primary care for systematic screening of HTN and CKD.

https://www.crd.york.ac.uk/prospero/, identifier CRD42024486068.

## Linked entities

- **Diseases:** Chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** infectious diseases (MESH:D003141), Hypertensive nephropathy (MESH:C563161), Proteinuria (MESH:D011507), stage 3-5 (MESH:D062706), Diabetic nephropathy (MESH:D003928), NCD (MESH:D000073296), obesity (MESH:D009765), Kidney Disease (MESH:D007674), CKD (MESH:D051436), weight loss (MESH:D015431), cancers (MESH:D009369), DM (MESH:D003920), ESRD (MESH:D007676), Vascular disease (MESH:D014652), CVD (MESH:D002318), Coronary Heart Disease (MESH:D003327), Dyslipidemia (MESH:D050171), death (MESH:D003643), BP (MESH:D006973), albuminuria (MESH:D000419), Glomerulonephritis (MESH:D005921), Disease (MESH:D004194)
- **Chemicals:** lipid (MESH:D008055), RAAS inhibitor (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926114/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12926114/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926114/full.md

---
Source: https://tomesphere.com/paper/PMC12926114